[Compound A: toxicology and clinical relevance]

Area of Science:

• Anesthesiology
• Toxicology
• Nephrology

Background:

• Volatile anesthetics like sevoflurane degrade with carbon dioxide absorbents.
• The primary degradant, Compound A, is a haloalkene known to be nephrotoxic in rats and nonhuman primates.
• Concerns exist regarding Compound A's potential nephrotoxicity in humans, particularly during low-flow anesthesia.

Purpose of the Study:

• To investigate the potential renal effects of Compound A production during sevoflurane anesthesia in humans.
• To compare renal function markers in surgical patients and volunteers exposed to sevoflurane under various conditions.

Main Methods:

• Assessment of standard renal function markers (creatinine clearance, BUN, creatinine) and experimental markers (urine protein, glucose, NAG, GST, AAP).
• Examination of surgical patients and volunteers undergoing anesthesia with sevoflurane at different flow rates and with different absorbents.
• Analysis of Compound A concentrations under various anesthetic conditions (low flow, high concentration, absorbent type, temperature, humidity).

Main Results:

• In surgical patients, low-flow sevoflurane or isoflurane anesthesia did not reveal significant renal effects.
• In volunteers, one study noted changes in experimental renal markers, but not conventional ones; other studies found no significant changes.
• No human case reports of Compound A-associated renal injury have been documented.

Conclusions:

• Current evidence suggests sevoflurane-induced Compound A production does not cause significant renal injury in humans.
• Observed nephrotoxicity in animal models may be due to metabolic pathway differences between rats and humans.
• Further research into the mechanism of Compound A nephrotoxicity is warranted, considering species-specific metabolic differences.